Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. - Wikidata - wikimedia - TriplyDB

Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma.

Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma.

http://www.wikidata.org/entity/Q34665749

about

Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program.LC-MS/MS determination of d-mannose in human serum as a potential cancer biomarker.Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy.

P2860

Q36358540-0FB73652-0623-49B4-8A62-1C86A1348DFD Q37359615-AC665C74-1CEA-4805-A1AB-C018062FB384 Q40378855-6D62498A-229A-4E68-8B9D-E6279E6C71F0 Q55108047-E8339142-5FE1-4D6F-86A4-B55CC90FDB90

P2860

Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma.

http://www.wikidata.org/entity/Q34665749

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@ast

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@en

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@nl

type

label

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@ast

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@en

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@nl

prefLabel

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@ast

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@en

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@nl

P1433

Q34665749-4FF4E908-2A32-429D-9113-B097FB36B654

P1476

Q34665749-7B0379F8-61E6-4771-80EB-248597C1F359

P2093

Q34665749-0E44F9AD-7F4E-4409-9CE9-6BD4BF35E3F6

Q34665749-1BD87D7F-7B22-43FA-B2C5-4BE7E79A4CB5

Q34665749-690E0D95-04BB-423E-A390-131CB90F1297

Q34665749-D4ACE4B8-0691-4E10-BF25-825D69222B52

Q34665749-FDFD5F24-8097-4BBE-9691-B8147BD1297A

P2860

Q34665749-28691AC5-908C-4801-B924-7AB96A028260

Q34665749-30D763D7-6B01-4083-8E46-20F9C62E98C8

Q34665749-35B1C3D4-0CDF-4090-B63B-288A765FD84E

Q34665749-3A03AA22-8E99-45B8-BA42-C1C12BB521E3

Q34665749-3FB482CC-ED0E-4AC5-8492-C729B0886F5C

Q34665749-4A83BFBB-C3FD-41FA-B0F1-39C4C5D19EB9

Q34665749-7E9E0474-8FCE-48E4-A47C-9CF6CC7001C8

Q34665749-8FBA2B1B-B654-422C-B49D-AB909963B6DA

Q34665749-94692E56-C137-4687-84E8-A0F863A3E30E

Q34665749-94966F18-45B1-4498-AC0E-DD9CEC574B9F

P2888

Q34665749-4D5959CE-220F-4565-A3A2-FFCF2A2DF782

P304

Q34665749-DECFB02F-508C-467A-B380-BB500B1CCE79

P31

Q34665749-22C12096-E43D-4545-B87B-18F64903AEE8

P356

Q34665749-3AF3124F-75D9-44B6-BAED-940E23BCC524

P433

Q34665749-5409B65E-6935-4145-9CEE-308BEB5F64E8

P478

Q34665749-5C16D428-EA7A-46DE-AEE4-C1814794867E

P50

Q34665749-0AB4B2DF-5832-4E25-8976-6A461DD42228

Q34665749-277464A2-31A5-427B-92CB-03A3D01A4365

Q34665749-AAC7C2F4-B249-403D-9D68-C46E2199B4F2

Q34665749-C86E48CB-D8FF-4BA3-800C-D41C7724A7C6

P577

Q34665749-BCF68461-533C-4B98-B188-1870F44B0E88

P6179

Q34665749-2DB8D30B-754B-42F2-A296-B00B2E1C3453

P698

Q34665749-989AE278-24D0-47E4-83EA-C4BB467937B5

P921

Q34665749-374B3112-A162-4E00-BAA9-EBBC25512067

P356

S00268-014-2835-1

P1433

World Journal of Surgery

P1476

Esophageal cancer management: ...... ccult advanced adenocarcinoma.

@en

P2093

Francesco Cavallin

http://www.w3.org/2001/XMLSchema#string

Giulia Noaro

http://www.w3.org/2001/XMLSchema#string

Luca Saadeh

http://www.w3.org/2001/XMLSchema#string

Mario Plebani

http://www.w3.org/2001/XMLSchema#string

Matteo Cagol

http://www.w3.org/2001/XMLSchema#string

P2860

Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.

Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.

The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.

Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Serum tumor markers in the management of ovarian, endometrial and cervical cancer.

Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?

P2888

s00268-014-2835-1

P304

424-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00268-014-2835-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033289842

http://www.w3.org/2001/XMLSchema#string

P698

25326423

http://www.w3.org/2001/XMLSchema#string

P921